HomeClinical TopicsCardio-PulmonaryFDA approves Kcentra for urgent reversal of anticoagulation in adults

FDA approves Kcentra for urgent reversal of anticoagulation in adults

Author(s):

On April 29, the U.S. Food and Drug Administration (FDA) approved Kcentra (Prothrombin Complex Concentrate, Human) for the urgent reversal of vitamin K antagonist (VKA) anticoagulation in adults with acute major bleeding. Plasma is the only other product approved for this use in the United States; Kcentra doesn’t require blood group typing or thawing, so it can be administered more quickly than frozen plasma. Read more.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Most Recent Content

For Nurse Practitioners

covid-19 virus illustration

Will Omicron Be More Contagious Than Delta?

If the first thing you heard about the omicron variant over the holiday weekend was that it is bad news, the second thing was...